Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis
By H. Kordasiewicz, L. Stanek, E. Wancewicz, C. Mazur, Melissa McAlonis, K. Pytel, Jonathan W. Artates, A. Weiss, Seng H. Cheng, L. Shihabuddin and 3 more. Neuron, 2012
699 citations recorded by the source corpus.
SUMMARY The primary cause of Huntington’s disease (HD) is expression of huntingtin with a polyglutamine expansion. Despite an absence of consensus on the mechanism(s) of toxicity, diminishing the synthesis of mutant huntingtin will abate toxicity if delivered to the key affected cells. With antisense oligonucleotides (ASOs) that catalyze RNase H-mediated degradation of huntingtin mRNA, we demonstrate that transient infusion into the cerebral spinal fluid of symptomatic HD mouse models not only delays disease progression, but mediates a sustained reversal of disease phenotype that persists longer than the huntingtin knockdown. Reduction of wild type huntingtin, along with mutant huntingtin, produces the same sustained disease reversal. Similar ASO infusion into non-human primates is shown to effectively lower huntingtin in many brain regions targeted by HD pathology. Rather than requiring continuous treatment, our findings establish a therapeutic strategy for sustained HD disease reversal produced by transient ASO-mediated diminution of huntingtin synthesis.
Subfields: Cellular and Molecular Neuroscience, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/42b2b6b1148843265c105bb0a677806ddbf50dea
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- Huntington's disease: a clinical review (2018, background): “In animal models this results in up to 80% sustained reduction in HTT mRNA levels [78].”